Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Stock Information for Portage Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Portage Biotech Inc.

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.